Exiqon A/S
Decisions of extraordinary general meeting

Exiqon A/S - Decisions at the extraordinary general meeting on 5 July 2016

Copenhagen, 2016-07-05 15:16 CEST (GLOBE NEWSWIRE) -- An extraordinary general meeting of Exiqon was held today, 5 July 2016, where the general meeting resolved to elect Peer M. Schatz, Roland Sackers and Axel Backheuer for the Company's supervisory board, while Erik Walldén, Thorleif Krarup, Michael Nobel, Per Wold-Olsen and Rodney Turner resigned.

At a meeting of the supervisory board held immediately after the extraordinary general meeting, the supervisory board elected Peer M. Schatz as chairman of the supervisory board and Roland Sackers as vice chairman of the supervisory board.

The composition of the supervisory board is as follows:

  • Peer M. Schatz, chairman
  • Roland Sackers
  • Axel Backheuer

At the same meeting of the supervisory board it was decided to appoint Mr. Brad Crutchfield as manager of the company. Mr. Crutchfield currently holds a position as Senior Vice President of QIAGEN N.V. and is responsible for QIAGEN N.V.' life science business. Mr. Crutchfield joined QIAGEN N.V. in 2015 and has over 30 years of experience in the life science industry, most recently as Vice President and General Manager EMEA for Illumina Inc. From 1985 to 2014, Mr. Crutchfield held positions of increasing responsibility with Bio-Rad Laboratories Inc., rising to Executive Vice President and President of The Life Science Group. Mr. Crutchfield also has extensive experience in applied markets, particularly food safety. In 2013 and 2014 he also served as a Director of NanoString Technologies, Inc. Mr. Crutchfield holds a Bachelor of Science in Physiology from the University of California at Davis, US.

Subsequent of the appointment of Mr. Crutchfield the registered management of the company consists of Mr. Crutchfield and Mr. Lars Kongsbak.

Additional information

Thomas Theuringer, telefon +49 2103 29 11826

Hans Henrik Chrois Christensen, telefon +45 4566 0888

About Exiqon

At Exiqon, we advance the research of when and where genes are expressed. We empower scientists across the world with best-in-class products and user-friendly business solutions designed to transform workflows in our industry. Exiqon operates in two business areas: Exiqon Life Sciences is a leading provider of flexible solutions for gene expression analysis. Academia, biotech and pharmaceutical companies around the world use Exiqon's research products to make ground-breaking discoveries. Exiqon Diagnostics collaborates with diagnostic and pharmaceutical companies to develop novel molecular diagnostic tests for early detection of diseases, which can help physicians make better treatment decisions. Exiqon is listed on Nasdaq Copenhagen. For more information about us, please visitwww.exiqon.com

Exiqon A/S published this content on 05 July 2016 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 05 July 2016 13:20:02 UTC.

Original documenthttps://cns.omxgroup.com/cdsPublic/viewDisclosure.action?disclosureId=718877&messageId=901124

Public permalinkhttp://www.publicnow.com/view/8D02AB834D6D8F64F1DD95B779A257DA795F476D